English Entry

 

 

 

您当前的位置: 首页 > 师资队伍 > 教授 研究员 > 正文

侯永忠 (博导)

 Email: houyz@mail.ujs.edu.cn

2012/7-现在。江苏大学,  研究员。

2007/11- 2012/7 博士后/research associate. University of Calgary, Canada.

2006/4 - 2007/11. 博士后. Kinki University, Japan. 2

2005/6 - 2006/2 博士后. University of Florida, USA .

研究方向

细胞信号通路与肿瘤发生机制

主要聚焦核受体蛋白调控肿瘤发生分子机制及药物开发。以人肿瘤细胞和小鼠为研究对象,探索并揭示细胞核受体蛋白PPARs PPARα PPARγPPARδ)调节肿瘤发生的细胞内信号网络机制(涉及蛋白磷酸化、泛素化;及细胞代谢、自噬等信号调控),基于这些分子机制筛选以PPARs 为靶点的天然或合成抗肿瘤化合物。

主持项目:

目前主持江苏省高层次“创新”“创业”人才引进计划项目,国家自然科学基金等项目。

获奖:

镇江市科技进步一等奖(2015),江苏省科技进步三等奖(2017)。

 

近年发表主要论文* 通讯作者)

1. Gou Q, Gong X, Jin J, Shi J*, Hou Y*. Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy.  Oncotarget. 2017;8(36):60704-60709.2017.

2. Zhang W, Xu Y, Xu Q, Shi H, Shi J*, Hou Y*. PPARδ promotes tumor progression via activation of Glut1   and SLC1-A5 transcription. Carcinogenesis. 2017;38(7):748-755.

3. Yuan S, Jin J, Chen L, Hou Y*, Wang H*. Naoxintong/PPARγ Signaling Inhibits Cardiac Hypertrophy via Activation of Autophagy. Evid Based Complement Alternat Med. 2017:3801976.

4. You M, Jin J, Liu Q, Xu Q, Shi J*, Hou Y*. PPARα Promotes Cancer Cell Glut1Transcription Repression. J Cell Biochem. 2017,118(6):1556-1562.

5. Zhang R, Jin J, Shi J*, Hou Y*. INGs are potential drug targets for cancer. J Cancer Res Clin  Oncol. 2017;143:189-197.

6.Xu H, Jin J, Chen L, Li C, Xu Q, Shi J, Zhao B, Hou Y*, Wang H*. Naoxintong/PPARαSignaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress. Evid Based Complement Alternat Med. 2016:4370381. doi: 10.1155/2016/4370381.

7. Yuan S, Jin J, Shi J*, Hou Y*.Inhibitor of growth-4 is a potential target for cancer therapy.  Tumour Biol. 2016;37:4275-9.

8. Xu Y, Jin J, Zhang Z, Zhang W, Gao J, Liu Q, Zhou C, Shi H, Hou Y*, Shi J*.   EGFR/MDM2 signaling promotes NFkB activation via PPARγ degradation.  Carcinogenesis, 2016;37:215-22.

9. Gao J, Liu Q, Xu Y, Gong X, Zhang R, Zhou C, Su Z, Jin J, Shi H, Shi J*, Hou Y*. PPARα  induces cell apoptosis by destructing Bcl2. Oncotarget. 2015. doi: 10.18632/oncotarget.5988.

10. You M, Yuan S, Shi J, Hou Y*. PPARδ signaling regulates colorectal cancer. Current Pharmaceutical Design. 2015; 21(21):2956-9

11. Hou Y*, Zhang Z, Xu Q, Wang H, Xu Y, Chen K. ING4 induces NFκB/p65 ubiquitin-dependent degradation. Oncogene. 2014, 33:1997-2003.

12. Hou Y*, Gao J, Xu H, Xu Y, Zhang Z, Xu Q, Zhang C. PPARγ E3 ubiquitin ligase regulates MUC1-C oncoprotein stability. Oncogene. 2014, 33:5619-25.

13. Hou Y, France M, Chadee K*. PPARγ functions as E3 ubiquitin ligase to terminate NFкB activation. Nature Communications. 2012, 3:1300.

 

返回首页
回首页